Sue Arata Posted May 24, 2019 Share Posted May 24, 2019 Hello, We are seeing an increase of patients on the new oncology drug for multiple myeloma (DARALEX/DARATUMUMAB) and I was wondering if anyone had any useful tips to share. Currently our procedure states to do a baseline ABSC prior to initiating the drug and to antigen type for at least Kell. Additionally, if the ABSC is positive in Gel, to rerun it in tube and to do an immediate spin crossmatch on Kell negative units (provided of course that the patient is Kell negative). Just wondering if this is how other places are handling these patients. Thanks, Sue Arata Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now